Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Christen Lykkegaard Andersen, Knud Juel, Hans Carl Hasselbalch & Ann-Dorthe Zwisler. (2017) A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clinical Epidemiology 9, pages 141-150.
Read now
Read now
Mads Emil Bjørn & Hans Carl Hasselbalch. (2017) Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology 10:5, pages 393-404.
Read now
Read now
Richard T. Silver & Hans Carl Hasselbalch. (2016) Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology 21:7, pages 387-391.
Read now
Read now
Articles from other publishers (8)
Hans Hasselbalch, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Trine A. Knudsen, Marko Lucijanić & Rajko Kusec. (2022) Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers 14:22, pages 5495.
Crossref
Crossref
Hans C. Hasselbalch & Richard T. Silver. (2021) New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. HemaSphere 5:12, pages e645.
Crossref
Crossref
Ghaith Abu-Zeinah, Spencer Krichevsky, Tatiana Cruz, Gabriela Hoberman, Diana Jaber, Niamh Savage, Claudia Sosner, Ellen K. Ritchie, Joseph M. Scandura & Richard T. Silver. (2021) Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia 35:9, pages 2592-2601.
Crossref
Crossref
Vibe Skov. (2020) Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers 12:8, pages 2194.
Crossref
Crossref
Rasmus K. Pedersen, Morten Andersen, Trine A. Knudsen, Zamra Sajid, Johanne Gudmand‐Hoeyer, Marc J. B. Dam, Vibe Skov, Lasse Kjær, Christina Ellervik, Thomas S. Larsen, Dennis Hansen, Niels Pallisgaard, Hans C. Hasselbalch & Johnny T. Ottesen. (2020)
Data‐driven analysis of
JAK2
V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
. Cancer Medicine 9:6, pages 2039-2051.
Crossref
Crossref
Hans Carl Hasselbalch & Morten Orebo Holmström. (2018) Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology 41:1, pages 5-19.
Crossref
Crossref
Richard T. Silver, Ariella C. Barel, Elena Lascu, Ellen K. Ritchie, Gail J. Roboz, Paul J. Christos, Attilio Orazi, Duane C. Hassane, Wayne Tam & Nicholas C. P. Cross. (2017) The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer 123:14, pages 2680-2687.
Crossref
Crossref
Hans Carl Hasselbalch & Mads Emil Bjørn. (2015) MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation 2015, pages 1-16.
Crossref
Crossref